In clinical trials, up to 20% of participants experienced nausea during the initial weeks of treatment
A significantly lower proportion of patients in the semaglutide OW cohort had other outpatient services (97.8% versus 99.7%, P = 0.0003), but the absolute difference was small
Similarly, it improved cerebral energy metabolism in ischemic rat brain (Suzuki et al., 2001) and prevented glutamate mediated neuronal toxicity and lipid peroxidation (Meja-Toiber et al., 2006)
By activating GLP-1 receptors, semaglutide helps: Stimulate insulin production when blood sugar is high Reduce glucagon secretion, which further lowers blood sugar Slow down digestion, promoting a feeling of fullness Decrease appetite by acting on brain centers controlling hunger The FDA has approved Ozempic for the treatment of type 2 diabetes, while Wegovy, a higher-dose formulation of semaglutide, is specifically approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity